Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
5.5
Expiration
Dec 24, 2026
DTE
41d
Moneyness
ITM
Intrinsic
$0.51
IBRX 5.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $2.58 | -21.10% | 1 | 9 |
| Nov 20, 2026 | 7d | — | — | 0 | 23 |
| Nov 27, 2026 | 14d | — | — | 0 | 0 |
| Dec 4, 2026 | 21d | $2.95 | +0.00% | 2 | 4 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $2.95 | -4.84% | 9 | 7,765 |
| Jan 21, 2028 | 434d | $4.18 | -3.69% | 1 | 3,712 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.